Department of Neonatology, School of Medicine, Pontificia Universidad Católica de Chile, Lira 40, Santiago, Chile.
Neonatal Intensive Care Unit, Hospital de Pediatría Prof. Dr. Juan P. Garrahan. Combate de Los Pozos 1850, Ciudad Autónoma de, CP 1245, Buenos Aires, Argentina.
J Pediatr Surg. 2023 Jul;58(7):1230-1234. doi: 10.1016/j.jpedsurg.2023.01.058. Epub 2023 Feb 15.
Mortality related to CDH is high, but with great variability among centers. There are few studies on patients with this condition born in South America which show poor outcomes. The goal of this study is to present the outcome of CDH in several high-volume quaternary centers in South America, ascertain the factors associated with lower mortality in our population, and compare our outcomes to those of the CDH Study Group (CDHSG).
The data from two South American centers were retrospectively analyzed and compared with contemporary data from other CDHSG participating centers. Patient demographic and clinical characteristics were also evaluated and compared.
Between 2013 and 2018, the two South American centers saw 335 patients with CDH with an overall survival rate of 73.1%. Survival for the high, intermediate, and low-risk groups as determined by the Brindle score was 50%, 70%, and 87%, respectively. In our cohort the strongest predictors of mortality were ECMO use and early PaCO. There were no significant differences in mortality between the two South American centers and the other CDHSG centers when adjusted by risk score, however, the South American centers had higher use of ECMO in the intermediate-risk group.
Quaternary South American centers had similar outcomes to CDHSG centers worldwide. The availability and coordination of centralized dedicated care allow more efficient use of scarce technical and professional resources in patients with CDH.
III.
先天性膈疝(CDH)相关死亡率较高,但各中心之间差异较大。关于在南美洲出生的患有这种疾病的患者的研究较少,这些研究显示出较差的结果。本研究的目的是展示南美洲几家大容量四级中心的 CDH 结果,确定与我们人群死亡率降低相关的因素,并将我们的结果与 CDH 研究组(CDHSG)进行比较。
回顾性分析了来自两个南美洲中心的数据,并与其他参与 CDHSG 的同期数据进行了比较。还评估和比较了患者的人口统计学和临床特征。
2013 年至 2018 年间,两个南美洲中心共收治 335 例 CDH 患者,总体生存率为 73.1%。根据 Brindle 评分确定的高、中、低风险组的生存率分别为 50%、70%和 87%。在我们的队列中,死亡率的最强预测因素是 ECMO 的使用和早期 PaCO2。在调整风险评分后,两个南美洲中心与其他 CDHSG 中心之间的死亡率没有显著差异,但是,南美洲中心在中危组中使用 ECMO 的比例更高。
南美洲四级中心的结果与全球 CDHSG 中心相似。集中专用护理的可用性和协调允许在 CDH 患者中更有效地利用稀缺的技术和专业资源。
III。